Form 8-K

8-K — Tempest Therapeutics, Inc.

Accession: 0001193125-26-207601

Filed: 2026-05-06

Period: 2026-05-06

CIK: 0001544227

SIC: 2834 (PHARMACEUTICAL PREPARATIONS)

Item: Regulation FD Disclosure

Item: Other Events

Item: Financial Statements and Exhibits

Documents

8-K — d93617d8k.htm (Primary)

EX-99.1 (d93617dex991.htm)

EX-99.2 (d93617dex992.htm)

GRAPHIC (g93617dsp010.jpg)

GRAPHIC (g93617dsp011.jpg)

GRAPHIC (g93617dsp012.jpg)

GRAPHIC (g93617dsp013.jpg)

GRAPHIC (g93617dsp014.jpg)

GRAPHIC (g93617dsp015.jpg)

GRAPHIC (g93617dsp016.jpg)

GRAPHIC (g93617dsp017.jpg)

GRAPHIC (g93617dsp018.jpg)

GRAPHIC (g93617dsp019.jpg)

GRAPHIC (g93617dsp020.jpg)

GRAPHIC (g93617dsp021.jpg)

GRAPHIC (g93617dsp022.jpg)

GRAPHIC (g93617dsp023.jpg)

GRAPHIC (g93617dsp024.jpg)

GRAPHIC (g93617dsp025.jpg)

GRAPHIC (g93617dsp026.jpg)

GRAPHIC (g93617dsp027.jpg)

GRAPHIC (g93617dsp028.jpg)

GRAPHIC (g93617dsp029.jpg)

GRAPHIC (g93617dsp030.jpg)

GRAPHIC (g93617dsp031.jpg)

GRAPHIC (g93617dsp032.jpg)

GRAPHIC (g93617g0506091656328.jpg)

XML — IDEA: XBRL DOCUMENT (R1.htm)

8-K

8-K (Primary)

Filename: d93617d8k.htm · Sequence: 1

8-K

false 0001544227 0001544227 2026-05-06 2026-05-06 0001544227 us-gaap:CommonStockMember 2026-05-06 2026-05-06 0001544227 us-gaap:SeriesAPreferredStockMember 2026-05-06 2026-05-06

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 6, 2026

Tempest Therapeutics, Inc.

(Exact name of Registrant as Specified in Its Charter)

Delaware

001-35890

45-1472564

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

2000 Sierra Point Parkway, Suite 400

Brisbane, California

94005

(Address of Principal Executive Offices)

(Zip Code)

Registrant’s Telephone Number, Including Area Code: (415) 798-8589

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading

Symbol(s)

Name of each exchange

on which registered

Common Stock, $0.001 par value

TPST

The Nasdaq Stock Market LLC

Series A Junior Participating Preferred Purchase Rights

N/A

The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01

Regulation FD Disclosure

On May 6, 2026, Tempest Therapeutics, Inc. (the “Company”) posted an updated corporate presentation, dated May 6, 2026, to the “News, Events & Presentations” subsection of the “Investors” tab on the Company’s website at www.tempesttx.com.

The information furnished in this Item 7.01 (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act or the Exchange Act, except as expressly provided by specific reference in such a filing.

Item 8.01

Other Events

On May 6, 2026, the Company issued a press release entitled “Tempest Presents Clinical Update at ISCT 2026 Annual Meeting.” A copy of the Company’s press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01

Financial Statements and Exhibits

(d) Exhibits.

Exhibit

No.

Description

99.1

Press release, dated May 6, 2026

99.2

Corporate Presentation dated May 2026

104

Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

TEMPEST THERAPEUTICS, INC.

Date: May 6, 2026

By:

/s/ Nicholas Maestas

Name:

Nicholas Maestas

Title:

Chief Financial Officer

EX-99.1

Filename: d93617dex991.htm · Sequence: 2

EX-99.1

Exhibit 99.1

Tempest Presents Clinical Update at ISCT 2026 Annual Meeting

•

100% complete response (“CR”) rate among all 15 CAR-T-naïve efficacy evaluable patients treated with TPST-2003 dual-targeting CD19/BCMA CAR-T across two ongoing Phase 1 trials

(REDEEM-1 and POEMS-1)

•

Favorable safety profile with no Grade >3 CRS or ICANS in REDEEM-1 trial evaluating TPST-2003 in relapsed/refractory multiple myeloma (“rrMM”)

•

100% CR as measured by normalization of serum vascular endothelial growth factor levels (“CRVEGF“) rate among all five efficacy evaluable patients in POEMS-1 trial evaluating TPST-2003 in the rare disease, POEMS syndrome

•

44 patients treated to date across three studies

•

Results support clinical benefit of parallel-structure dual-targeting CAR architecture in patients with rrMM,

including in patients with extramedullary disease (“EMD”)

•

Median progression free survival of 23.1 months, including in patients with EMD, if replicated in

registrational trial, would position TPST-2003 as potentially class-leading therapy for rrMM

Brisbane, CA, May 6, 2026

– Tempest Therapeutics, Inc. (Nasdaq: TPST) (“Tempest”) today presents its most recent clinical data from its lead dual-targeting chimeric antigen receptor T-cell (“CAR-T”) therapy product candidate, TPST-2003, at the International Society for Cell & Gene Therapy (“ISCT”) Scientific Annual Meeting in Dublin, Ireland. Updates include the latest

data from the ongoing REDEEM-1 Phase 1/2a trial evaluating TPST-2003, as well as progress in Tempest’s other dual-targeting CAR-T pipeline programs.

Earlier this year, Tempest announced positive interim data from REDEEM-1, including a 100% complete response

(“CR”) rate among all six efficacy then-evaluable patients according to the International Myeloma Working Group (“IMWG”) uniform response criteria, as well as a favorable safety profile. Today’s clinical update

more than doubles the previous dataset, achieving a 100% CR rate among all 15 CAR-T-naïve efficacy evaluable patients across two ongoing Phase 1 trials – REDEEM-1 evaluating TPST-2003 in relapsed/refractory multiple myeloma (“rrMM”) (10/10 according to the IMWG uniform response criteria) and POEMS-1 evaluating

TPST-2003 in POEMS syndrome (5/5 CRVEGF).

To date, a total of 44 patients have received one infusion of TPST-2003, including 24 patients in a prior

Phase 1/2 investigator-initiated trial (“IIT”) evaluating TPST-2003 in rrMM, 13 patients in the ongoing REDEEM-1 trial, and seven patients in the ongoing

POEMS-1 trial, representing one of the largest datasets evaluating a CD19/BCMA dual-targeting CAR-T therapy.

All 10 CAR-T-naïve patients currently evaluable for efficacy in the REDEEM-1 trial – three treated at dose level 1 (1 x 106 cells/kg), three at dose level 2 (2 x 106

cells/kg), and four at dose level 3 (3 x 106 cells/kg) – achieved a CR according to the IMWG uniform response criteria. A single patient, who had previously received a BCMA-targeting CAR-T, did not respond. Among 29 CAR-T-naïve evaluable patients with measurable disease at baseline across REDEEM-1 and the prior Phase 1/2 IIT, including 18 patients with EMD, the overall response rate (“ORR”) was 100% (29/29) according to the IMWG uniform response criteria.

In the POEMS-1 trial, as of the January 31, 2026 data cutoff, all five evaluable patients had achieved a CRVEGF within two months of being administered TPST-2003. No dose-limiting toxicities were observed in any of the treated patients.

“The results that we are presenting at ISCT this week support our belief that TPST-2003 could offer a life-saving option for patients with rrMM, and, if

approved, may outperform first-generation single-targeting CAR-T therapies, in particular in patients with EMD” said Dr. Matt Angel, President and Chief Executive Officer of Tempest. “We are

excited by the potential to offer patients who have relapsed from multiple prior lines of therapy a treatment that may achieve up to complete remission of their cancer.”

The observed safety profile (no Grade >3 CRS or ICANS), together with the consistency of responses observed in the

REDEEM-1 trial continue to support Tempest’s plan to pursue its objective of meeting with the FDA to discuss initiating a U.S. registrational study later this year.

Presentation Details

REDEEM-1, a multicenter open-label Phase 1/2a study of a BCMA/CD19 dual-targeting

CAR-T therapy in patients with relapsed/refractory multiple myeloma including those with extramedullary disease. Abstract #1268. Oral Presentation, May 6, 2026

(12:00-13:00 GMT) & Poster Reception, May 7, 2026 (18:00-19:30 GMT), Immunotherapy Session. Presenter: Dr. Matt Angel.

About TPST-2003

TPST-2003 is an autologous CD19/BCMA dual-targeting CAR-T therapy designed to improve response depth and durability in

patients with relapsed/refractory multiple myeloma (“rrMM”) through a parallel dual-targeting CAR structure designed to address tumor heterogeneity and antigen escape. TPST-2003 is being developed in China by Tempest’s partner,

Novatim Immune Therapeutics (“Novatim”). Under its agreement with Novatim, Tempest has the exclusive right to develop TPST-2003 outside of China, India, Turkey, and Russia.

About REDEEM-1

REDEEM-1 (Study nos. CTR20233309/NCT06223646) is a Phase 1/2a clinical trial evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk cytogenetics and patients

with extramedullary disease. The REDEEM-1 trial has a targeted full enrollment of 32 patients. The REDEEM-1 trial is sponsored and being conducted by Tempest’s

partner, Novatim Immune Therapeutics, with a total of eight clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), The First Affiliated Hospital of Nanchang University (Dr. Fei Li), Peking

University First Hospital (Dr. Yujin Dong), Henan Cancer Hospital (Dr. Baijun Fang), Shanxi Provincial Cancer Hospital (Dr. Liping Su), The Second Xiangya Hospital of Central South University (Dr. Hongling Peng), The First

Affiliated Hospital of China Medical University (Dr. Xiaojing Yan), and The Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences, Peking Union Medical College (Dr. Dehui Zou).

About POEMS-1

POEMS-1 is a Phase 1 clinical trial (Study nos. CTR20242409/NCT06518876) evaluating TPST-2003 in patients with POEMS, a rare blood disorder caused by abnormal plasma cells. The

POEMS-1 trial has a targeted full enrollment of 12 patients. The POEMS-1 trial is sponsored and being conducted by Tempest’s partner, Novatim, with a total of

three clinical sites registered in China: Peking Union Medical College Hospital (Dr. Jian Li; lead site), Xuanwu Hospital Capital Medical University (Dr. Wanling Sun), and West China Hospital, Sichuan University (Dr. Yu Wu).

Additional Clinical Trial Evaluating TPST-2003

A Phase 1/2 IIT (Study no. NCT04714827) is evaluating TPST-2003 in patients with relapsed/refractory multiple myeloma, including patients with high-risk

cytogenetics and patients with extramedullary disease. The IIT is sponsored and being conducted by Tempest’s partner, Novatim, with a total of two clinical sites registered in China: Shanghai Fourth People’s Hospital (Dr. Weijun Fu;

lead site) and Shanxi Provincial Cancer Hospital (Dr. Liping Su).

About Tempest Therapeutics

Tempest Therapeutics is a clinical-stage biotechnology company developing a pipeline of advanced CAR-T cell therapy

product candidates to treat cancer. Tempest is headquartered in Brisbane, California. More information about Tempest can be found on the company’s website at https://www.tempesttx.com.

Forward-Looking Statements

This press release contains

forward-looking statements (including within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended, concerning Tempest Therapeutics, Inc. These statements

may discuss goals, intentions, and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as assumptions made by, and

information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as

“may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,”

“project,” “intend,” “goal”, “suggest”, “target” and other similar expressions. All statements that are not historical facts are forward-looking statements, including but not limited to,

statements regarding: Tempest Therapeutics’ plan to present data from clinical trials, including the REDEEM-1 trial and the POEMS-1 trial; the design, initiation,

progress, timing, scope and results of clinical trials; the planned advancement of a diversified next-generation CAR-T pipeline; anticipated therapeutic benefit and regulatory development of Tempest

Therapeutics’ product candidates, including TPST-2003; Tempest Therapeutics’ ability to achieve its operational plans, and Tempest’s plan to pursue its objective of meeting with the FDA to discuss initiating a U.S. registrational

study later this year. All forward-looking statements in this press release are based on Tempest Therapeutics’ current expectations, estimates and projections about its industry as well as management’s current beliefs and expectations of

future events only as of today and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and

uncertainties include, but are not limited to Tempest

Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; unexpected safety or efficacy data observed during

preclinical or clinical trials; the possibility that results from prior clinical trials and preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation

or enrollment rates that are lower than expected; loss of key personnel; changes in expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology

companies; and unexpected litigation or other disputes. These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of Tempest

Therapeutics’ Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Securities and Exchange Commission (“SEC”) on March 30, 2026, and in other documents

filed by Tempest Therapeutics from time to time with the SEC. Except as required by applicable law, Tempest Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements,

whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should

not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics.

Investor Contacts:

Sylvia Wheeler

Wheelhouse Life Science Advisors

swheeler@wheelhouselsa.com

Aljanae Reynolds

Wheelhouse Life Science Advisors

areynolds@wheelhouselsa.com

EX-99.2

Filename: d93617dex992.htm · Sequence: 3

EX-99.2

Exhibit 99.2

® Developing Advanced Therapies for Cancer Patients

Forward Looking Statements This presentation contains forward-looking statements (including within the meaning

of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended (the “Securities Act”) concerning Tempest Therapeutics, Inc. (“Tempest Therapeutics”).

These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the management of Tempest Therapeutics, as well as

assumptions made by, and information currently available to, management of Tempest Therapeutics. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and

include words such as “may,” “will,” “should,” “would,” “could”, “expect,” “anticipate,” “plan,” “likely,” “believe,”

“estimate,” “project,” “intend,” and other similar expressions. All statements that are not historical facts are forward-looking statements, including any statements regarding: the potential benefits of Tempest

Therapeutics’ expanded oncology pipeline; the design, initiation, progress, timing, scope and results of clinical trials; the anticipated therapeutic benefit, opportunity to improve patient care, and regulatory development of Tempest

Therapeutics’ product candidates; Tempest Therapeutics’ ability to deliver on potential value-creating milestones; the potential use of Tempest Therapeutics’ product candidates to treat additional indications; Tempest

Therapeutics’ ability to achieve its operational plans; and the sufficiency of Tempest Therapeutics’ cash and cash equivalents. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and

uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: Tempest Therapeutics’

strategies, prospects, plans, expectations or objectives for future operations; the progress, scope or timing of the development of Tempest Therapeutics’ product candidates; the benefits that may be derived from any future products or the

commercial or market opportunity with respect to any of Tempest Therapeutics’ future products; unexpected safety or efficacy data observed during preclinical or clinical trials; the possibility that results from prior clinical trials and

preclinical studies may not necessarily be predictive of future results; past results may not be indicative of future results; clinical trial site activation or enrollment rates that are lower than expected; loss of key personnel; changes in

expected or existing competition; changes in the regulatory environment; risks relating to volatility and uncertainty in the capital markets for biotechnology companies; unexpected litigation or other disputes; Tempest Therapeutics’ ability to

protect its intellectual property rights; Tempest Therapeutics’ need for additional capital to fund its planned programs and operations and to continue to operate as a going concern; Tempest Therapeutics’ anticipated operations,

financial position, ability to raise capital to fund operations, revenues, costs or expenses; statements regarding future economic conditions or performance; statements of belief and any statement of assumptions underlying any of the foregoing.

These and other factors that may cause actual results to differ from those expressed or implied are discussed in greater detail in the “Risk Factors” section of the company’s Annual Report on Form

10-K filed with the Securities and Exchange Commission (SEC) on March 30, 2026, as well as in other filings the company may make with the SEC in the future. Except as required by applicable law, Tempest

Therapeutics undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not

be relied upon as representing Tempest Therapeutics’ views as of any date subsequent to the date of this press release and should not be relied upon as prediction of future events. In light of the foregoing, investors are urged not to rely on

any forward-looking statement in reaching any conclusion or making any investment decision about any securities of Tempest Therapeutics. This presentation discusses product candidates that are under clinical study and which have not yet been

approved for marketing by the U.S. Food and Drug Administration. No representation is made as to the safety or effectiveness of these product candidates for the use for which such product candidates are being studied. This presentation incorporates

publicly-available third-party data that Tempest Therapeutics has not independently verified. There are risks inherent in conducting cross-trial comparisons and the results should be interpreted with caution. The presentation of such third-party

data does not represent a head-to-head comparison of how TPST-2003 performed against any other third-party drug candidate or study. Rather, such third-party data has

been pulled by us from publicly-available sources for supplemental informational purposes, only. Tempest Therapeutics cautions you that any comparisons against third-party data set forth herein should not be viewed as a side-by-side comparison, and you should not rely on the completeness or accuracy of Tempest Therapeutics’ presentation of the results of any third-party drug candidate

in these slides, due to differences in study design, how other companies quantify or qualify eligibility criteria, and how results are recorded, among other distinguishing factors and uncertainties. Because Tempest Therapeutics may be unaware of or

may not adequately present various distinguishing factors and uncertainties, the comparisons set forth herein may not properly present such third-party data, which may differ materially from the data as presented here. Investors are encouraged to

independently review third party data and should not rely on Tempest Therapeutics’ presentation of such data (including any such data placed in comparison with the performance of TPST-2003) as a single measure to evaluate Tempest

Therapeutics’ business. The trademarks included herein are the property of the owners thereof and are used for reference purposes only. Such use should not be construed as an endorsement of such products.

Selected Potential Value-Inflecting Milestones through Q4 2027 2026 2027 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Phase 1/2 IIT REDEEM-1 Phase 2b (China TPST-2003 results and Phase 2a registrational) REDEEM-1 Tech transfer enrollment start Phase 2b (China) CD19/BCMA Dual

CAR-T Phase 2b (U.S. Phase 1/2a enrollment start complete File IND (U.S.) (China File BLA r/r Multiple Myeloma registrational) (China) interim registrational) interim data (China) with EMD data POEMS-1 Pre-IND (U.S.) interim data Phase 2b (U.S. and POEMS Syndrome Tech transfer Phase 1 (China) registrational) start interim data enrollment start Toxicology Phase 1/2

IIT Phase 1/2a TPST-2206 complete Phase 1/2 IIT (China) Phase 1/2 IIT (China) CD70/CD70 Dual CAR-T GMP (China) interim enrollment (China) results enrollment Renal Cell Carcinoma manufacturing data start start

start TPST-3003 Phase 1/2 IIT Phase 1/2 IIT Phase 1/2a GMP Phase 1/2 IIT (China) Universal CD19/BCMA (China) (China) results enrollment start manufacturing (China) interim Dual CAR-T enrollment start data

Phase 1 (U.S.) start File IND (U.S.) r/r Multiple Myeloma enrollment start TPST-4003 Phase 1/2 IIT Phase 1/2 IIT Phase 1 (U.S.) In vivo CD19/BCMA (China) (China) interim File IND (U.S.) enrollment Dual CAR-T

enrollment data start SLE start All activities shown above in bold are 100% funded by strategic partner

TPST-2003 Dual Targeting CD19/BCMA CAR-T

TPST-2003 CD19/BCMA CAR-T TPST-20031,2 is the world’s first

parallel-structure dual-target CAR-T cell therapy for rrMM with EMD & POEMS syndrome • REDEEM-1 Phase 1/2a (rrMM) and

POEMS-1 Phase 1 (POEMS syndrome) Dual-target CAR-T structure • 44 patient target – 32 in REDEEM-1 and 12 in POEMS-1 • 20 patients dosed as of May 6, 2026 – 13 in REDEEM-1, 7 in POEMS-1 • 100% CR rate among CAR-T-naïve patients (15/15) – REDEEM-1 (10/10 CR) and POEMS-1 (5/5 CRVEGF)

efficacy-evaluable as of March 31, 2026 and January 31, 2026, respectively • No grade ≥3 CRS, no grade ≥3 ICANS in REDEEM-1, Phase 1 enrollment complete (12/12), Phase 2a currently

enrolling, first patient dosed May 2, 2026 • Phase 1/2 Investigator-Initiated Trial (rrMM) – Enrollment complete (24 patients) • 100% ORR among all 19 patients with measurable disease at baseline, 89.5% CR rate (17/19), 100% CR

rate at highest dose level (5/5) • Median PFS of 23.1 months across all patients (24/24), median PFS of 23.1 months in EMD patients (15/15) • All evaluable patients at month 12 were MRD-negative

(5/5) 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144

(2024) 923- 924., 2Li, J., et. al. “REDEEM-1, A MULTICENTER OPEN-LABEL PHASE 1/2A STUDY OF A BCMA/CD19 DUAL-TARGETING CAR-T THERAPY IN PATIENTS WITH

RELAPSED/REFRACTORY MULTIPLE MYELOMA INCLUDING THOSE 6 WITH EXTRAMEDULLARY DISEASE”. Cytotherapy 28 (2026) 1268., Interim data update, May 6, 2026. “CRS” Cytokine Release Syndrome, “EMD” Extramedullary Disease,

“CR” Complete Response, “CRVEGF” Complete Response as measured by normalization of serum vascular endothelial growth factor levels, “ORR” Overall Response Rate, “PFS” Progression-Free Survival,

“ICANS” Immune effector cell-associated neurotoxicity syndrome, “MRD” Minimal Residual Disease.

TPST-2003 Dual CAR-T for rrMM1: Study Design Multicenter, open label,

IIT study FPI Jan.2021, LPI Jun.2024, Patients continued to be assessed for response Data cut-off Jul.25th,2024, Efficacy evaluable patients N=23, Safety Set N=20, PKPS N=20 Key Inclusion criteria Primary

endpoint: Dose Level: • Relapsed/ Refractory Multiple • AE and SAE • DL 1: 1.0x106 CAR-T cells/kg Myeloma (R/R MM) • Clinical recommended dose • DL2: 2 .0 x 106 CAR-T cells/kg • R/R MM pts with ~1 prior lines of • DL3: 3.0x106 CAR-T cells/kg therapy including proteasome Secondary endpoint: inhibitor (Pl), and

immunomodulatory • PK/PD drug (IMiDs), and/or anti-CD38 • PFS, ORR, DoR, OCR, OS ICF and Apheresis KQ-2003 QC Lymphodepletion KQ-2003 DLT Follow up Screening

Manufacturing Release (Flu/Cy*3 days) Infusion Evaluation Assessment visits , , , ‘ ‘ ‘ ‘ ... ~ ‘ D-47 D-27

D-6 DO D1~ D28 M2 M3 MG M9 M12 M15 M18 M21 M24 PKPS : Pharmacokinetics Parameter Set; AE: Adverse Event; SAE: Serious Adverse Event; PFS: Progression Free Survival ; ORR: Objective Response Rate; DoR: Duration

of Response; OCR: Disease Control Rate; OS: Overall Survival; ICF: Informed Consent Form ; QC: Quality control 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with

Relapsed/Refractory ~TEMPEST 8 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924. ~ THERAPEUT I CS

TPST-2003 Dual CAR-T for rrMM1: Baseline Characteristics Baseline

Characteristics Total {N=23) Baseline Characteristics Total {N=23) Median age Crange ) 64 (52-77) Median prior lines of therapy, n(%) 5 (2-11) Male, n(%) 12 (52.2) Prior

auto-SCT, n(%) 9 (39.1) ECOG performance-status score, n(%) Refractory, n(%) ¦ 0 14 (60.9) ¦ Pl refractory 23 (100) ¦ 1 8 (34.8) 2 ¦ IMiD refractory 23 (100) ¦ 1 (4.3)

¦ Triple-refractory 21 (91.3) Type of myeloma, n(%) ¦ Quadru-refractory 16 (69.6) ¦ lgG 13 (56.5) ¦ Penta-refractory 6 (26.1) ¦ lgA 6 (26.1) ¦ lgD 1 (4.3) Extramedullary disease, n(%) 14 (60.9) ¦

Light chain 3 (13.0) Bridging therapy 18 (78.3) High-risk profile8 , n(%) 12/19c {63.2) Refractory to last therapy 18 (78.3) Double-hitb, n(%) 4/19 (21.1) a FISH By mSMART 3.0 b By presence two of del(17p), t(4;14),t(14;16),t(14;20),gain 1q, or p53

mutation c The rest 4 pts (all with EMO ) without clonal plama cells in BM at baseline for FISH analysis 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with

Relapsed/Refractory ~TEMPEST 9 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924.

TPST-2003 Dual CAR-T for rrMM1: Hematological Response 01003

Hematological ORR* N=18 1 [ 02003 DL N=3 N=10 N=5 N=18 N=3 100% 02002 80% 01010 -02008 ~ 60% - 0 01011 CJ) 40% 0:: sCR 02011 20% 33.30% DL2 02015 CR N=11 0% 02013 1//////////////////////// ....... VGPR DL1 DL2 DL3 All Pts 02017 ¦ VGPR

¦ sCR/CR PR 02020 02019 SD MRD Assessment** N=20 02021 N= 18 N=11 N=5 Relapse after CR—100% 02023 Non hematological 0 ~ - 80% 02007 measurable indicators Q.) ro 02012 0:: 60% ¦ PD Q.) 02016 > 40% :;:; ¦ Death Ctl 02018

Ol DL3 Q.) 20% MRD-negative C N=9 02025 0 0% 0:: 02026 MRD-positive ~ M3 M6 M1 2 02027 ..... Ongoing ¦ M RD+ ¦ M RD- 02028 02029 •••►

Survival fo llow-up *Pts had Hematological measurable indicators: N=18(18/23); **NGF Sensitivity: a threshold of 10-5 nucleated cells 0 3 6 9 12 15 18 21 24 27 1Jiang, H., et. al. “A Prospective

Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory Multiple Myeloma Including Those with ~TEMPEST Extramedullary Disease”. Blood 144 (2024)

923-924. “sCR” stringent complete response, “CR” complete response, “VGPR” very good partial response, “PR” partial response, “SD” stable disease,

“PD” 10 ~ THERAPEUT I CS progressive disease, “MRD” minimal residual disease, “ORR” objective response rate, “Pts” patients

TPST-2003 Dual CAR-T for rrMM1: EMD PET Response Hematological PET

Response Of EMD Response PET ORR: 85.7% (12/14) N=1 N=7 N=6 N=14 DL1[ 02003—100% 02008—80% 02015—•••► 02013 0 -;,12_ 60% DL2 Cl) 02017 0.... 40% CMR 02020 PMR 20% 02019 •••► 02021 SMD

0% 02018 Hematologic PD DL 1 DL2 DL3 All Pts •••► ¦ 02025 ¦ SMD ¦ PMR ¦ CMR ¦ Death DL3 02026 02027 —► Ongoing Best Reduction Size 02028 •••► Survival follow-up of soft tissue plasmacytomas 02029 - 0 3 6 9 12 15 18 21 ——·-···-······-···-· ·-·

——·—···· ·-······ -75%~-100% TABLE 7. Proposed Refinement of PET

Response Criteria After Therapy PET Response After 50% l Therapy Response Criteria Complete metabolic Uptake c;; liver activity in BM sites and Fls previously involved (including extramedullary and paramedullary response disease [DS score 1-3]) Partial metabolic Decrease in number and/or activity of BM/Fls present at baseline, but persistence of lesion(s) with uptake > liver response activity (DS score 4 or 5)

-50% ~ -75% Stable metabolic disease No significant change in BM/Fls compared with baseline 14% Progressive metabolic New Fls compared with baseline consistent with

myeloma disease Abbreviations: BM, bone marrow; DS, Deauville scale; FL, focal lesion; PET, positron emission tomography. Elena Zamagni, et al. J Clin Oneal. 2021 Jan 10;39(2):1 16-125. doi:

10.1200/JC0.20.00386 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory ~TEMPEST 12 Multiple Myeloma Including Those with Extramedullary

Disease”. Blood 144 (2024) 923-924.

TPST-2003 Dual CAR-T for rrMM1: EMD PET Response Case-02008 58-yo male Penta-refractory, 11 prior LOT Case-02003 55-yo female Quad-refractory, 5 prior LOT M3: VGPR & PMR -c, M6: sCR MRD- & CMR for 21 + mos M3: VGPR & CMR-c, M9: sCR MRD- & CMR for 23+ mos 1Jiang, H., et. al. “A Prospective

Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory ~TEMPEST 13 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024)

923-924. ~ THERAPEUT I CS

TPST-2003 Dual CAR-T for rrMM1: Survival All EMO NonEJ.,D 100% 100% ~

15% li 111, ~· 2’ ~ 50%, iii, 2 > ;;;J, (I), ,5~ staVmelfian=23.1(95%ct 13.7--:W,,) E:M D: ::::;u ( 9 s • 1: 6.a- ) NOfl- EM D : S.6 ( 9511GI :

:?.07—) 0% 0% 0 3 6 9 2 15 18 21 24 21 30 0 3 6 9 12 5 18 21 21 30 ·me, (month) EMD ime (mol’l1!h} Number at ris!k - Nu.mber a.t l’lsk ! : I Non 15 15 13 11 11 10 8 •6 .2 2 0 23 20 17 17 15 13 8 3 ED ~ !;Alll 2~ •

and Non- II D 9 8 1 6 6 5 5 2 2 ‘ ‘ ‘ ‘ ‘ ‘ ‘ ‘ ‘ ‘ g, ‘ ‘ ‘ ‘ ‘ ‘ 0 J 6 9 12 15 18 2 1 24 27 30 0 J •6 12

15 18 21 24 27 J8 Time (monlh) EMD T“me ( om J All rrMM Patients rrMM Patients with EMD No. of subjects 24 15 Median follow-up 30.1 months Median PFS 23.1 months 23.1 months 1-year PFS 74.4% 73.3% ✓ Median PFS for EMD patients was 23.1 months vs. Carvykti’s 13.8 months 1Li, J., et. al. “REDEEM-1, A MULTICENTER OPEN-LABEL PHASE

1/2A STUDY OF A BCMA/CD19 DUAL-TARGETING CAR-T THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE ~TEMPEST 14 MYELOMA INCLUDING THOSE WITH EXTRAMEDULLARY DISEASE”. Cytotherapy 28 (2026) 1268., Interim

data update, May 6, 2026. ~ THERAPEUT I CS

TPST-2003 Dual CAR-T for rrMM1: Safety Profile TEAEs1 TEAEs TRAEs TRAEs

N=20 CRS2 (n,%) ICANS (n,%) N=20 (n,%) Gr~ 3 (n,%) (n,%) Gr~ 3 (n,%) Grade 1-2 17 (85.0) 3 (15.0) Hematologic (TEAEs ~ 5% All Grades) Grade 3 1 (5.0) 2 (10.0) Leukopenia 17(85.0) 14(70.0) 16(80.0) 12(60.0)

Thrombocytopenia 17(85.0) 8(40.0) 16(80.0) 6(30.0) Grade 4-5 0 (0) 0 (0) Anemia 16(80.0) 8(40.0) 15(75.0) 6(30.0) All Grade 18 (90.0) 5 (25.0) Neutropenia 16(80.0) 10(50.0) 15(75.0) 9(45.0) Lymphopenia

16(80.0) 16(80.0) 14(70.0) 11 (55.0) Non-Hematologic (TEAEs ~ 5% All Grades) CRS any grade Median (days) Min, Max (days) LOH increase 16(80.0) 0 7(35.0) 0 Time to onset 4 1, 9 Hyperferritinaemia 15(75.0) 0

14(70.0) 0 Elevated D-dimer 13(65.0) 0 13(65.0) 0 Duration 4 2, 15 Hypoalbuminemia 11 (55.0) 0 0 0 Urinary tract infection 8(40.0) 2(10.0) 2(10.0) 0 MT increase 8(40.0) 0 8(40.0) 0 ICANS any grade Median

(days) Min, Max (days) Hypogam maglobuli naemia 12(60.0) 0 12(60.0) 0 Diarrhoea 7(35.0) 0 2(10.0) Time to onset 10 8, 23 0 FOP increase 8(40.0) 0 8(40.0) 0 Duration 3 1,9 AST increase 8(40.0) 0 8(40.0) 0 Pneumonia 8(40.0) 6(30.0) 5(25.0) 4(20.0)

□ All CRS and ICANS were manageable and resolved by SOC Prolonged PT 6(30.0) 0 6(30.0) 0 ( Tocilizumab, vasopressors and dexamethasone) Hypokalemia 4(20.0) 3(15.0) 3(15.0) 1(5.0) □ Totally 4 deaths occurred , including 2 for

therapy-related Upper respiratory infection 4(20.0) 1(5.0) 0 0 pneumonia on 062 and 0103, and 2 deaths for PD Hypofibrinogenemia 4(20.0) 0 4(20.0) 0 1AE were graded according to CTCAE v5.0, 2CRS criteria (ASBMT consensus grading); FOP: Fibrin

degradation products, ALT: Alanine aminotransferase, AST: Aspartate aminotransferase, LOH: lactate dehydrogenase; PT: Prothrombin time; CRS: Cytokine release syndrome, ICANS: !EC-associated neurotoxicity

Syndrome, PD: Disease progression 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T Therapy in Patients with Relapsed/Refractory ~TEMPEST 15 Multiple Myeloma Including Those with

Extramedullary Disease”. Blood 144 (2024) 923-924. ~ THERAPEUT I CS

TPST-2003 Dual CAR-T for rrMM1: Expansion and Persistence CAR-T cell positivity rate-time plot-BCMA+ (PKPS) CAR-T cell VCN-time plot (PKPS) 270000 90 <( 250000 ~ 230000 80 Cl 210000 :::1. ~

~ 70 ui 190000 u QI 00 60 ‘ii 170000 2 8 150000 ~ so ~ ai 130000 1 40 ‘iii i 110000 \ 0 a. 30 ~ 90000 \ ai >, 70000 \ \ ~ “ 20 C. 0 50000 \ u ,_ t3 10 0 30000 .... u 10000 QI > -10000 -10

..,.__—————-~———-~ -30000 Lymphod DO DI D3 DS D7 DIO Dl4 D21 D28 M2 M3 M6 M9 MIS M21 M24 Lymphod DO D1 D3 DS D7 D10 D14 D21 D28 M2 M3 M6 M9 M15 M21 M24 epletion Visit time epletion Visit time I-+- l .01ClOlq: -0 · 2.0~lOJ’itJ -+- ‘.lll~ l lllq I 1 —- l.Q IC 1O/k,g -e. 2.0 IC 101kg -+- 3.0 IC

10,‘kg I CAR-T cell positivity rate-time plot-CD19+ (PKPS) CAR-T cell VCN PK DL1 DL2 DL3 35 parameter (PKPS) (N=3) (N=10) (N=7) a, 30 8 25 Median T max(D) 14 11

.50 9 d, ! 20 ·;; Median Cmax(copies/µg) 97014.00 168218.00 83878.00 ~ 15 8_ ] 10 Median AUC _ lD ·copies/µg) 716037.01 1430939.38 437946.63 1-;- 0 Cl:’. u <I: 5 Median

AUCo-int(D ·copies/µg) 1168278.89 1705951.87 509249 .27 -5 Among pts with 6 and 12 mo’ follow-up, 66.7% (10/15) and 50 .0% (4/8) had

..,.__———-+———-~~~-~-~~ Lymphod DO DI D3 DS D7 DIO Dl4 D21 D28 M2 M3 M6 M9 MIS M21 M24 epletion Visit time detectable CAR+T cells above the level of quantification (2 cells/µL) in PB. I-+- l .0 ~10/ki -e—2.0• IO~ -+- :SD ~lO~ I 1Jiang, H., et. al. “A Prospective Investigator-Initiated Phase 1/2 Study of BCMA/CD19 Dual-Targeting CAR T

Therapy in Patients with Relapsed/Refractory ~TEMPEST 16 Multiple Myeloma Including Those with Extramedullary Disease”. Blood 144 (2024) 923-924. ~ THERAPEUT I CS

TPST-2003 Dual CAR-T for rrMM: Conclusions TPST-20031,2 is the

world’s first parallel-structure dual-target CAR-T cell therapy for rrMM with EMD & POEMS syndrome • REDEEM-1 Phase 1/2a (rrMM) and POEMS-1 Phase 1 (POEMS syndrome) • 44 patient target – 32 in REDEEM-1 and 12 in POEMS-1 • 20 patients dosed as of

May 6, 2026 – 13 in REDEEM-1, 7 in POEMS-1 • 100% CR rate among

CAR-T-naïve patients (15/15) – REDEEM-1 (10/10 CR) and POEMS-1 (5/5 CRVEGF)

efficacy-evaluable as of March 31, 2026 and January 31, 2026, respectively • No grade ≥3 CRS, no grade ≥3 ICANS in REDEEM-1, Phase 1 enrollment complete (12/12), Phase 2a currently

rate at highest dose level (5/5) • Median PFS of 23.1 months across all patients (24/24), median PFS of 23.1 months in EMD patients (15/15) • All evaluable patients at month 12 were MRD-negative

144 (2024) 923-924., 2Li, J., et. al. “REDEEM-1, A MULTICENTER OPEN-LABEL PHASE 1/2A STUDY OF A BCMA/CD19 DUAL-TARGETING

CAR-T THERAPY IN 17 THERAPEUT I CS PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA INCLUDING THOSE WITH EXTRAMEDULLARY DISEASE”. Cytotherapy 28 (2026) 1268., Interim data update, May 6, 2026.

TPST-2003 Shows Similar Favorable Safety Profile to Approved BCMA CAR-T

TPST-20031 Abecma Carvykti (BMS)2 (J&J/Legend)3 Target CD19, BCMA BCMA BCMA Stage REDEEM-1 Phase 1/2a Approval Approval Indication rrMM rrMM rrMM Target Dose 1x106 cells/kg 2x106 cells/kg 3x106 cells/kg

420x106 cells 0.75x106 cells/kg CRS% (N) 66.7% (2) 100% (3) 100% (6) 85% 84% CRS% Gr≥3 (N) 0% 0% 0% 9.3% 4% ICANS% (N) 0% 0% 16.7% (1) 28% 13% ICANS% Gr ≥3 (N) 0% 0% 0% 4% 2% CRS and ICANS were manageable and reversible, showing a

favorable safety profile comparable to existing therapies 1Li, J., et. al. “REDEEM-1, A MULTICENTER OPEN-LABEL PHASE 1/2A STUDY OF A BCMA/CD19 DUAL-TARGETING CAR-T

THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA INCLUDING THOSE WITH EXTRAMEDULLARY DISEASE”. Cytotherapy 28 (2026) 1268., Interim data update, May 6, 2026. 2. Abecma TM label at https://www.abecmahcp.com/safety/crs,

accessed Nov 2025. 3. Carvykti TM label at ~TEMPEST 18

TPST-2003 Performance Relative to Approved Therapies TPST-20031 Abecma Carvykti (BMS)2 (J&J/Legend)3 Target

CD19, BCMA BCMA BCMA Stage Phase 1/2 IIT Approval Approval Indication rrMM rrMM rrMM KarMMa CARTITUDE-1 Trial IIT (NCT 03361748) (NCT 03548207) Number of 15 50 19 EMD patients Median PFS of EMD patients 23.1

months 7.9 months 13.8 months “Patients… with EMD demonstrate significantly inferior Day 90 ORR [following treatment with Abecma ] and presence of EMD is an independent risk factor for inferior PFS.” - Saurabh Zanwar et al., ASCO

2024 Annual Meeting 1Li, J., et. al. “REDEEM-1, A MULTICENTER OPEN-LABEL PHASE 1/2A STUDY OF A BCMA/CD19 DUAL-TARGETING CAR-T THERAPY IN PATIENTS WITH

RELAPSED/REFRACTORY MULTIPLE MYELOMA INCLUDING THOSE WITH EXTRAMEDULLARY DISEASE”. Cytotherapy 28 (2026) 1268., Interim data update, May 6, 2026. 2. Zanwar S, Sidana S, Shune L, et al. Impact of extramedullary multiple myeloma on outcomes

with idecabtagene vicleucel.J Hematol Oncol. 2024;17(1):42. 3. Sidana, S. 2025 ASCO Annual Meeting. https://www.asco.org/abstracts-presentations/ABSTRACT496242, accessed November 2025. Certain data in this presentation are based on a 19 cross-trial

comparison and are not based on head-to-head clinical trials. Cross trial comparisons are inherently limited and may suggest misleading similarities or differences in

outcomes. Results of head-to-head comparisons may differ significantly from those set forth herein.

Small Molecule Programs Amezalpat (TPST-1120)

First-in-Class PPAR�� Antagonist TPST-1495 First-in-Class Dual EP2/4

Antagonist

® Developing Advanced Therapies for Cancer Patients May 6, 2026

GRAPHIC

Filename: g93617dsp010.jpg · Sequence: 8

Binary file (230326 bytes)

Download g93617dsp010.jpg

GRAPHIC

Filename: g93617dsp011.jpg · Sequence: 9

Binary file (326707 bytes)

Download g93617dsp011.jpg

GRAPHIC

Filename: g93617dsp012.jpg · Sequence: 10

Binary file (235916 bytes)

Download g93617dsp012.jpg

GRAPHIC

Filename: g93617dsp013.jpg · Sequence: 11

Binary file (220355 bytes)

Download g93617dsp013.jpg

GRAPHIC

Filename: g93617dsp014.jpg · Sequence: 12

Binary file (68950 bytes)

Download g93617dsp014.jpg

GRAPHIC

Filename: g93617dsp015.jpg · Sequence: 13

Binary file (249780 bytes)

Download g93617dsp015.jpg

GRAPHIC

Filename: g93617dsp016.jpg · Sequence: 14

Binary file (322075 bytes)

Download g93617dsp016.jpg

GRAPHIC

Filename: g93617dsp017.jpg · Sequence: 15

Binary file (313886 bytes)

Download g93617dsp017.jpg

GRAPHIC

Filename: g93617dsp018.jpg · Sequence: 16

Binary file (284037 bytes)

Download g93617dsp018.jpg

GRAPHIC

Filename: g93617dsp019.jpg · Sequence: 17

Binary file (306078 bytes)

Download g93617dsp019.jpg

GRAPHIC

Filename: g93617dsp020.jpg · Sequence: 18

Binary file (274125 bytes)

Download g93617dsp020.jpg

GRAPHIC

Filename: g93617dsp021.jpg · Sequence: 19

Binary file (250243 bytes)

Download g93617dsp021.jpg

GRAPHIC

Filename: g93617dsp022.jpg · Sequence: 20

Binary file (240014 bytes)

Download g93617dsp022.jpg

GRAPHIC

Filename: g93617dsp023.jpg · Sequence: 21

Binary file (181745 bytes)

Download g93617dsp023.jpg

GRAPHIC

Filename: g93617dsp024.jpg · Sequence: 22

Binary file (378438 bytes)

Download g93617dsp024.jpg

GRAPHIC

Filename: g93617dsp025.jpg · Sequence: 23

Binary file (251023 bytes)

Download g93617dsp025.jpg

GRAPHIC

Filename: g93617dsp026.jpg · Sequence: 24

Binary file (216191 bytes)

Download g93617dsp026.jpg

GRAPHIC

Filename: g93617dsp027.jpg · Sequence: 25

Binary file (186937 bytes)

Download g93617dsp027.jpg

GRAPHIC

Filename: g93617dsp028.jpg · Sequence: 26

Binary file (175885 bytes)

Download g93617dsp028.jpg

GRAPHIC

Filename: g93617dsp029.jpg · Sequence: 27

Binary file (91800 bytes)

Download g93617dsp029.jpg

GRAPHIC

Filename: g93617dsp030.jpg · Sequence: 28

Binary file (186436 bytes)

Download g93617dsp030.jpg

GRAPHIC

Filename: g93617dsp031.jpg · Sequence: 29

Binary file (215366 bytes)

Download g93617dsp031.jpg

GRAPHIC

Filename: g93617dsp032.jpg · Sequence: 30

Binary file (230326 bytes)

Download g93617dsp032.jpg

GRAPHIC

Filename: g93617g0506091656328.jpg · Sequence: 31

Binary file (6867 bytes)

Download g93617g0506091656328.jpg

XML — IDEA: XBRL DOCUMENT

XML

Filename: R1.htm · Sequence: 33

v3.26.1

Document and Entity Information

May 06, 2026

Document And Entity Information [Line Items]

Amendment Flag

false

Entity Central Index Key

0001544227

Document Type

8-K

Document Period End Date

May 06, 2026

Entity Registrant Name

Tempest Therapeutics, Inc.

Entity Incorporation State Country Code

Entity File Number

001-35890

Entity Tax Identification Number

45-1472564

Entity Address, Address Line One

2000 Sierra Point Parkway

Entity Address, Address Line Two

Suite 400

Entity Address, City or Town

Brisbane

Entity Address, State or Province

Entity Address, Postal Zip Code

94005

City Area Code

(415)

Local Phone Number

798-8589

Written Communications

false

Soliciting Material

false

Pre Commencement Tender Offer

false

Pre Commencement Issuer Tender Offer

false

Entity Emerging Growth Company

false

Common Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title

Common Stock, $0.001 par value

Trading Symbol

TPST

Security Exchange Name

NASDAQ

Series A Preferred Stock [Member]

Document And Entity Information [Line Items]

Security 12b Title

Series A Junior Participating Preferred Purchase Rights

Security Exchange Name

NASDAQ

- Definition

Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.

+ References

No definition available.

+ Details

Name:

dei_AmendmentFlag

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Area code of city

+ References

No definition available.

+ Details

Name:

dei_CityAreaCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.

+ References

No definition available.

+ Details

Name:

dei_DocumentPeriodEndDate

Namespace Prefix:

dei_

Data Type:

xbrli:dateItemType

Balance Type:

Period Type:

duration

- Definition

The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.

+ References

No definition available.

+ Details

Name:

dei_DocumentType

Namespace Prefix:

dei_

Data Type:

dei:submissionTypeItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 1 such as Attn, Building Name, Street Name

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine1

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Address Line 2 such as Street or Suite number

+ References

No definition available.

+ Details

Name:

dei_EntityAddressAddressLine2

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the City or Town

+ References

No definition available.

+ Details

Name:

dei_EntityAddressCityOrTown

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Code for the postal or zip code

+ References

No definition available.

+ Details

Name:

dei_EntityAddressPostalZipCode

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Name of the state or province.

+ References

No definition available.

+ Details

Name:

dei_EntityAddressStateOrProvince

Namespace Prefix:

dei_

Data Type:

dei:stateOrProvinceItemType

Balance Type:

Period Type:

duration

- Definition

A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityCentralIndexKey

Namespace Prefix:

dei_

Data Type:

dei:centralIndexKeyItemType

Balance Type:

Period Type:

duration

- Definition

Indicate if registrant meets the emerging growth company criteria.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityEmergingGrowthCompany

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.

+ References

No definition available.

+ Details

Name:

dei_EntityFileNumber

Namespace Prefix:

dei_

Data Type:

dei:fileNumberItemType

Balance Type:

Period Type:

duration

- Definition

Two-character EDGAR code representing the state or country of incorporation.

+ References

No definition available.

+ Details

Name:

dei_EntityIncorporationStateCountryCode

Namespace Prefix:

dei_

Data Type:

dei:edgarStateCountryItemType

Balance Type:

Period Type:

duration

- Definition

The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityRegistrantName

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b-2

+ Details

Name:

dei_EntityTaxIdentificationNumber

Namespace Prefix:

dei_

Data Type:

dei:employerIdItemType

Balance Type:

Period Type:

duration

- Definition

Local phone number for entity.

+ References

No definition available.

+ Details

Name:

dei_LocalPhoneNumber

Namespace Prefix:

dei_

Data Type:

xbrli:normalizedStringItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 13e

-Subsection 4c

+ Details

Name:

dei_PreCommencementIssuerTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14d

-Subsection 2b

+ Details

Name:

dei_PreCommencementTenderOffer

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Title of a 12(b) registered security.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection b

+ Details

Name:

dei_Security12bTitle

Namespace Prefix:

dei_

Data Type:

dei:securityTitleItemType

Balance Type:

Period Type:

duration

- Definition

Name of the Exchange on which a security is registered.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 12

-Subsection d1-1

+ Details

Name:

dei_SecurityExchangeName

Namespace Prefix:

dei_

Data Type:

dei:edgarExchangeCodeItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Exchange Act

-Number 240

-Section 14a

-Subsection 12

+ Details

Name:

dei_SolicitingMaterial

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- Definition

Trading symbol of an instrument as listed on an exchange.

+ References

No definition available.

+ Details

Name:

dei_TradingSymbol

Namespace Prefix:

dei_

Data Type:

dei:tradingSymbolItemType

Balance Type:

Period Type:

duration

- Definition

Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef

-Publisher SEC

-Name Securities Act

-Number 230

-Section 425

+ Details

Name:

dei_WrittenCommunications

Namespace Prefix:

dei_

Data Type:

xbrli:booleanItemType

Balance Type:

Period Type:

duration

- References

No definition available.

+ Details

Name:

tpst_DocumentAndEntityInformationLineItems

Namespace Prefix:

tpst_

Data Type:

xbrli:stringItemType

Balance Type:

Period Type:

duration

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type:

- Details

Name:

us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type:

Balance Type:

Period Type: